Last reviewed · How we verify
Mannose
At a glance
| Generic name | Mannose |
|---|---|
| Also known as | D-Mannose Oral Powder, D-[U-13C] |
| Sponsor | Kantonsspital Aarau |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- An Efficacy Study of a Dietary Supplement Drink Mix for Urinary Health Improvement (NA)
- Synbiotics in Patients at RIsk fOr Preterm Birth (NA)
- Association Between Plasma Level of Mannose Binding Lectin and Human Reproduction
- A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections (NA)
- Smoking, Stress, HIV and Mobile Technology (NA)
- An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS) (PHASE1)
- The Effects of Mannose Supplementation on Glycosylation and Protein Levels in Human Sera (NA)
- PRObiotics for KIdney Transplantation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mannose CI brief — competitive landscape report
- Mannose updates RSS · CI watch RSS
- Kantonsspital Aarau portfolio CI